Get Fit Bharat

Tag: Training

HomeTraining

October 31, 2024 – Biosergen AB (“Biosergen”), a clinical-stage biotechnology company developing therapies for life-threatening fungal diseases, today announced the completion of treatment for the first cohort of patients in its proof-of-concept clinical trial for its antifungal drug-candidate BSG005. The cohort consisted of five patients: two completely recovered, two saw …

As of 31 October 2024, the total number of shares in Betsson AB (publ) (the “Company”) amounts to 142,729,838 and the total number of votes amounts to 278,035,838. These are divided into 15,034,000 class A shares equaling 150,340,000 votes, 123,448,405 class B shares carrying the same number of votes and …

Fondia Plc Company release 31.10.2024 at 6.45 p.m. EET   Fondia – Acquisition of own shares 31.10.2024   Fondia Plc   First North Finland   Date 31.10.2024 Exchange transactions Buy Share class FONDIA Amount, shares 276 Average price/share, EUR 6,092029 Total price, EUR 1681,40         The shares …

FIDELITY JAPAN TRUST PLC (the 'Company')     TRANSACTION IN OWN SHARES     The Board of the Company announces that it has bought into Treasury     Number of shares repurchased: 23,350 Date of transaction: 31 October 2024 Average share price paid per share (GBp): 154.030 Lowest share price paid per share (GBp): 154.000 …

FIDELITY ASIAN VALUES PLC (the 'Company')     TRANSACTION IN OWN SHARES     The Board of the Company announces that it has bought into Treasury     Number of shares repurchased: 15,000 Date of transaction: 31 October 2024 Average share price paid per share (GBp): 508.000 Lowest share price paid per share (GBp): 506.000 …

Atomic Ambitions Expansion Adds Nuclear Power and More STOCKHOLM - 31 October 2024 - The secrets of radioactivity unlock new strategic and development options in Atomic Ambitions, a new expansion for Millennia, the historical 4X strategy game from C Prompt Studios and Paradox Interactive. Power your empire with nuclear plants, …

Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous autoinjector for weekly maintenance dosing after …